Shuangshuang Shi1, Haojie Chen1, Hanqing Wang1, JianFeng Wan1, Yi Shi2, Jia Li2, Shuo Wang2, Jie Shi2, Jianying Lv2, Tong Wu3, Longlong Wang2, Fengyuan Sun4. 1. Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, 300384, China. 2. The School of Medicine, Nankai University, Tianjin, 300071, China. 3. Sichuan Eye Hospital, AIER Eye Hospital Group, No. 153, Tianfu Fourth Street, High-tech Zone, Chengdu, 610047, China. 4. Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, 300384, China. eyesunfengyuan@163.com.
Abstract
PURPOSE: Uveal melanoma (UM) is the most common intraocular malignant tumor in adults. Due to the lack of effective treatments for metastatic UM, the survival of UM has not changed over the past 3 decades. Therefore, it is important to identify essential genes regulating the metastasis of UM. METHODS: In this study, a genome-wide CRISPR knockout screen in an orthotopic mouse model of UM was performed to identify the regulatory genes conferring the metastatic phenotype. Loss-of-function analyses were performed to explore the function of G protein pathway suppressor 2 (GPS2) in UM metastasis in vitro and in vivo. RNA sequencing was performed to investigate the molecular mechanism underlying the function of GPS2 as a tumor suppressor in UM. RESULTS: Among the highest-ranking genes, we found several validated tumor suppressors, such as SHPRH, GPS2, PRPH2, and hsa-mir-1229; GPS2 was chosen as the candidate gene for further studies. GPS2 was lower expressed in the tumor tissues of UM patients. Furthermore, knocking-down GPS2 promoted the proliferation and metastatic abilities of UM cells both in vivo and in vitro. Finally, analysis of the transcriptome data revealed that silencing GPS2 upregulates oncogenic signaling pathways MAPK and PI3K-Akt, and in the meantime downregulates tumor suppressor signaling pathway Slit/Robo in UM cells. CONCLUSION: Altogether, our study proved that the GPS2 gene functions as a tumor suppressor and might be a novel potential therapeutic target for UM treatment.
PURPOSE: Uveal melanoma (UM) is the most common intraocular malignant tumor in adults. Due to the lack of effective treatments for metastatic UM, the survival of UM has not changed over the past 3 decades. Therefore, it is important to identify essential genes regulating the metastasis of UM. METHODS: In this study, a genome-wide CRISPR knockout screen in an orthotopic mouse model of UM was performed to identify the regulatory genes conferring the metastatic phenotype. Loss-of-function analyses were performed to explore the function of G protein pathway suppressor 2 (GPS2) in UM metastasis in vitro and in vivo. RNA sequencing was performed to investigate the molecular mechanism underlying the function of GPS2 as a tumor suppressor in UM. RESULTS: Among the highest-ranking genes, we found several validated tumor suppressors, such as SHPRH, GPS2, PRPH2, and hsa-mir-1229; GPS2 was chosen as the candidate gene for further studies. GPS2 was lower expressed in the tumor tissues of UM patients. Furthermore, knocking-down GPS2 promoted the proliferation and metastatic abilities of UM cells both in vivo and in vitro. Finally, analysis of the transcriptome data revealed that silencing GPS2 upregulates oncogenic signaling pathways MAPK and PI3K-Akt, and in the meantime downregulates tumor suppressor signaling pathway Slit/Robo in UM cells. CONCLUSION: Altogether, our study proved that the GPS2 gene functions as a tumor suppressor and might be a novel potential therapeutic target for UM treatment.
Authors: Valeria Amodeo; Deli A; Joanne Betts; Stefano Bartesaghi; Ying Zhang; Angela Richard-Londt; Matthew Ellis; Rozita Roshani; Mikaella Vouri; Sara Galavotti; Sarah Oberndorfer; Ana Paula Leite; Alan Mackay; Aikaterini Lampada; Eva Wessel Stratford; Ningning Li; David Dinsdale; David Grimwade; Chris Jones; Pierluigi Nicotera; David Michod; Sebastian Brandner; Paolo Salomoni Journal: Cell Rep Date: 2017-07-11 Impact factor: 9.423
Authors: Darshan S Chandrashekar; Bhuwan Bashel; Sai Akshaya Hodigere Balasubramanya; Chad J Creighton; Israel Ponce-Rodriguez; Balabhadrapatruni V S K Chakravarthi; Sooryanarayana Varambally Journal: Neoplasia Date: 2017-07-18 Impact factor: 5.715
Authors: Maria Sofia Basile; Emanuela Mazzon; Andrea Russo; Santa Mammana; Antonio Longo; Vincenza Bonfiglio; Matteo Fallico; Rosario Caltabiano; Paolo Fagone; Ferdinando Nicoletti; Teresio Avitabile; Michele Reibaldi Journal: PLoS One Date: 2019-01-17 Impact factor: 3.240
Authors: Stefanie Chan; Emma Smith; Yuan Gao; Julian Kwan; Benjamin C Blum; Andrew M Tilston-Lunel; Isabella Turcinovic; Xaralabos Varelas; Maria Dafne Cardamone; Stefano Monti; Andrew Emili; Valentina Perissi Journal: Front Cell Dev Biol Date: 2021-01-07